Evaluating the Effectiveness of Rituximab in Children with Steroid-Dependent or Frequently Relapsing Nephrotic Syndrome Associated with MCD or FSGS - Scorecard - MDSpire
Advertisement
Evaluating the Effectiveness of Rituximab in Children with Steroid-Dependent or Frequently Relapsing Nephrotic Syndrome Associated with MCD or FSGS
Clinical Scorecard: Evaluating the Effectiveness of Rituximab in Children with Steroid-Dependent or Frequently Relapsing Nephrotic Syndrome Associated with MCD or FSGS
At a Glance
Category
Detail
Condition
Steroid-Dependent or Frequently Relapsing Nephrotic Syndrome (SDNS/FRNS)
Key Mechanisms
Rituximab targets CD20 to reduce relapses in nephrotic syndrome.
Target Population
Pediatric patients with biopsy-proven MCD or FSGS.
Care Setting
Pediatric nephrology clinics.
Key Highlights
All 42 patients achieved clinical remission; 90.5% attained complete remission.
Relapse rates decreased to 35.7% within 1 year post-rituximab treatment.
No significant difference in relapse rates between different dosing regimens.
Rituximab was well tolerated with no major adverse effects reported.
Higher relapse-free survival in FSGS compared to MCD, though results require caution due to small sample size.
Guideline-Based Recommendations
Diagnosis
Biopsy-proven MCD or FSGS in patients with SDNS/FRNS.
Management
Consider rituximab as a treatment option for SDNS/FRNS.
Monitoring & Follow-up
Regular follow-ups including laboratory tests for urine protein, serum albumin, creatinine, eGFR, and B-cell counts.
Risks
Potential for infections and other adverse effects associated with immunosuppressive therapy.
Patient & Prescribing Data
Children diagnosed with SDNS/FRNS due to MCD or FSGS.
Rituximab administered at 375 mg/m2 per infusion, with a maximum of 500 mg.
Clinical Best Practices
Administer prophylactic treatment for pneumocystis jirovecii pneumonia during rituximab therapy.
Tailor immunosuppression duration based on individual patient response.
